TransMedics Group (NASDAQ:TMDX) Hits New 12-Month Low – What’s Next?

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price hit a new 52-week low on Thursday . The company traded as low as $57.90 and last traded at $58.02, with a volume of 2203853 shares traded. The stock had previously closed at $60.44.

Analysts Set New Price Targets

TMDX has been the topic of a number of recent analyst reports. Robert W. Baird dropped their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. TD Cowen dropped their price target on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Oppenheimer reiterated an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Price Performance

The stock has a market capitalization of $1.92 billion, a P/E ratio of 60.85 and a beta of 2.12. The business’s 50 day simple moving average is $71.50 and its two-hundred day simple moving average is $118.10. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s revenue was up 63.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.12) EPS. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. The trade was a 4.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is owned by insiders.

Institutional Trading of TransMedics Group

A number of hedge funds have recently bought and sold shares of the business. State of Alaska Department of Revenue bought a new stake in shares of TransMedics Group during the 3rd quarter worth $2,560,000. Charles Schwab Investment Management Inc. increased its holdings in TransMedics Group by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after buying an additional 6,634 shares during the last quarter. Zacks Investment Management bought a new stake in TransMedics Group in the third quarter worth about $1,607,000. Vaughan Nelson Investment Management L.P. boosted its stake in TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after acquiring an additional 64,360 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in TransMedics Group by 665.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after acquiring an additional 64,872 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.